Biological response modifiers render tumor cells susceptible to autologous effector mechanisms by influencing adhesion receptors

• Published in: Leukemia & lymphoma Vol. 10; no. 1-2; p. 25
• Main Authors: Schirren, C A, Völpel, H, Hoffmann, J C, Henning, S W, Qiao, L, Autschbach, F, Dengler, T J, Döhner, H, Meuer, S C
• Format: Journal Article
• Language: English
• Published: United States 1993
• Subjects: Antigens, CD - analysis; CD11 Antigens; CD58 Antigens; Cell Adhesion Molecules - analysis; Cell Adhesion Molecules - physiology; Cell Line; Cell Line, Transformed; Cytokines - pharmacology; Cytotoxicity, Immunologic; Humans; Intercellular Adhesion Molecule-1; Leukemia, T-Cell - immunology; Membrane Glycoproteins - analysis
• ISSN: 1042-8194
• DOI: 10.3109/10428199309147353

Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/CD58 and CD11a/18/CD54 interactions in cellular immune responses directed towards freshly recovered human T cell leukemias. Downregulation of CD54 and CD58 were observed to correlate with enhanced numbers of blasts in circulation and lack of susceptibility to killing by autologous cytotoxic lymphocytes. Furthermore, culturing tumor cells with recombinant TNF-alpha conditioned medium resulted in reinduction of CD54 and CD58 expression and susceptibility to lymphocyte mediated resulted in reinduction of CD54 and CD58 expression and susceptibility to lymphocyte mediated lysis in vitro. Our findings support the view that adhesion molecules play a pivotal role for tumor cell biology in vivo and stress the point that successful immunotherapy of malignant disease may be facilitated by influencing not only the immune response itself but also adhesion molecules on the malignant tumor targets.